Quantamental Technologies LLC Acquires 2,400 Shares of PerkinElmer, Inc. (NYSE:PKI)

Quantamental Technologies LLC grew its stake in shares of PerkinElmer, Inc. (NYSE:PKI) by 69.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,872 shares of the medical research company’s stock after purchasing an additional 2,400 shares during the period. Quantamental Technologies LLC’s holdings in PerkinElmer were worth $566,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quadrant Capital Group LLC purchased a new stake in shares of PerkinElmer during the 1st quarter valued at approximately $25,000. Lindbrook Capital LLC purchased a new stake in shares of PerkinElmer during the 4th quarter valued at $25,000. Citizens Financial Group Inc RI purchased a new stake in shares of PerkinElmer during the 4th quarter valued at $32,000. Penserra Capital Management LLC purchased a new stake in shares of PerkinElmer during the 4th quarter valued at $35,000. Finally, Financial Gravity Wealth Inc. purchased a new stake in shares of PerkinElmer during the 1st quarter valued at $52,000. Hedge funds and other institutional investors own 96.25% of the company’s stock.

In other PerkinElmer news, Director Alexis P. Michas sold 2,118 shares of the company’s stock in a transaction that occurred on Thursday, February 21st. The shares were sold at an average price of $92.96, for a total value of $196,889.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Daniel R. Tereau sold 1,200 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $93.27, for a total transaction of $111,924.00. Following the completion of the transaction, the insider now owns 5,839 shares of the company’s stock, valued at $544,603.53. The disclosure for this sale can be found here. Insiders have sold 55,274 shares of company stock valued at $5,238,106 over the last 90 days. 1.80% of the stock is currently owned by company insiders.

PerkinElmer stock traded up $0.80 during trading hours on Wednesday, hitting $86.30. The stock had a trading volume of 703,623 shares, compared to its average volume of 669,286. PerkinElmer, Inc. has a 12-month low of $71.31 and a 12-month high of $103.00. The stock has a market capitalization of $9.53 billion, a PE ratio of 23.91, a price-to-earnings-growth ratio of 1.52 and a beta of 1.22. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.17 and a current ratio of 1.68.

PerkinElmer (NYSE:PKI) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. The firm had revenue of $648.70 million during the quarter, compared to analyst estimates of $645.38 million. PerkinElmer had a net margin of 8.89% and a return on equity of 15.98%. The business’s revenue for the quarter was up .7% on a year-over-year basis. During the same period in the previous year, the business posted $0.63 earnings per share. As a group, equities research analysts forecast that PerkinElmer, Inc. will post 4.05 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be given a dividend of $0.07 per share. The ex-dividend date is Thursday, July 18th. This represents a $0.28 annualized dividend and a yield of 0.32%. PerkinElmer’s dividend payout ratio (DPR) is 7.76%.

PKI has been the topic of several research reports. Zacks Investment Research cut shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Saturday, April 13th. Piper Jaffray Companies raised their price objective on shares of PerkinElmer to $104.00 and gave the company an “overweight” rating in a research report on Friday, February 1st. UBS Group set a $92.00 price objective on shares of PerkinElmer and gave the company a “hold” rating in a research report on Saturday, February 2nd. Goldman Sachs Group raised shares of PerkinElmer from a “neutral” rating to a “buy” rating and set a $115.00 target price on the stock in a report on Tuesday, April 9th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $41.00 target price on shares of PerkinElmer in a report on Friday, May 3rd. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $82.32.

TRADEMARK VIOLATION NOTICE: “Quantamental Technologies LLC Acquires 2,400 Shares of PerkinElmer, Inc. (NYSE:PKI)” was originally published by Sundance Herald and is the property of of Sundance Herald. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://sundanceherald.com/2019/05/22/quantamental-technologies-llc-has-566000-holdings-in-perkinelmer-inc-pki.html.

PerkinElmer Company Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Featured Article: Do back-end load funds outperform no-load funds?

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply